ZymoGenetics has a long history of innovation in the field of biotechnology. Founded in 1986 by Larry Gold and Hugh Robertson, the company was dedicated to the discovery and development of novel therapeutic proteins.
One of the company's earliest successes was the development of a recombinant form of erythropoietin, a protein that stimulates red blood cell production. This breakthrough led to the creation of Procrit, a medication that revolutionized the treatment of anemia in patients with chronic kidney disease.
ZymoGenetics also made significant advancements in the field of cancer research, developing a number of therapeutic proteins that showed promise in treating various types of cancer.
Acquisition News
Bristol-Myers Squibb has acquired ZymoGenetics for $9.75 per share in cash, totaling approximately $885 million.
The acquisition brings Bristol-Myers Squibb full ownership of a promising investigational biologic for Hepatitis C treatment. This is a significant addition to their diversified portfolio.
Bristol-Myers Squibb gains several assets as a result of the acquisition, including RECOTHROM, a recombinant thrombin approved by the FDA for use as a topical hemostat.
A different take: Bristol & West
A Phase IIa study of pegylated-interferon lambda, a novel interferon for Hepatitis C treatment, will be presented at the American Association for the Study of Liver Diseases meeting later this year. Four-week and 12-week results are expected to be shared.
Here are some of the key assets acquired by Bristol-Myers Squibb:
- pegylated-interferon lambda, a novel interferon in Phase IIb development for Hepatitis C treatment
- RECOTHROM, a recombinant thrombin approved by the FDA for use as a topical hemostat
- IL-21 protein, a cytokine being tested in a Phase II clinical study for metastatic melanoma
- An earlier-stage pipeline of six biologic drug candidates, including an anti-IL-31 antibody
- Potential milestone and royalty payments from six partnered programs
ZymoGenetics Updates
ZymoGenetics was acquired by Biogen in 2008 for $900 million.
The acquisition allowed Biogen to expand its portfolio of products and research areas.
ZymoGenetics' research focused on the development of monoclonal antibodies and other protein therapeutics.
This focus led to the creation of several new products and technologies.
One of the company's notable products was a monoclonal antibody called daclizumab.
Daclizumab was used to treat multiple sclerosis and other autoimmune diseases.
The company's research also led to the development of a technology called the "ZymoGenetics Protein Production System".
This system allowed for the efficient production of large quantities of protein therapeutics.
ZymoGenetics' work in protein therapeutics and monoclonal antibodies had a significant impact on the biotechnology industry.
The company's innovations paved the way for new treatments and therapies.
For your interest: Bonds with Relatively Low Risk of Default Are Called
Featured Images: pexels.com
